glp 1 agonist statpearls Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon The Multifaceted Nature of GLP-1:
Description
[DOI] [PubMed] [Google Scholar] 36.Melson E., Ashraf U., Papamargaritis D., Davies M

Leading in the GLP-1 agonist diabetes arena are Eli Lillys recently approved Mounjaro (tirzepatide) and Novo Nordisks Ozempic (semaglutide), which has been a top seller for Novo since it first launched in 2017

Chollet, F

Major players including Novo Nordisk and Eli Lilly maintain substantial commercial footprints, competing aggressively on efficacy claims, patient support programs, and contracting strategies

Their effects on bowel transit lower in the gut appear more variable and may differ between individuals and medications

In addition, post-hoc sensitivity analyses were performed by excluding the prediabetic population (SELECT trial [8]) in Fig
